Pfizer is globally removing the sickle cell disease treatment pill, Oxbryta, due to high risks of severe safety events, including deaths. The decision comes after Pfizer acquired the maker, Global Blood Therapeutics, in 2022 for $5.4 billion. The drug was initially approved in 2019 as a new way to treat the inherited blood disorder. Pfizer stated that the risks associated with Oxbryta, including an increased risk of pain crises and fatal events, outweighed the benefits. This decision represents a significant setback for a drug that was once embraced as a promising treatment option for sickle cell disease.
Source link
Pfizer pulls sickle cell treatment Oxbryta off global markets
